February 14, 2026
The long-awaited GIANT clinical trial which aims to determine whether the combination of immunotherapy drugs (Nivolumab and Relatlimab) with conventional treatment can meaningfully improve outcomes for glioblastoma patients, has officially been launched in the US. The trial will involve multiple cancer centers and use a two-stage approach: first assessing safety in a small group of newly diagnosed patients, then evaluating efficacy in a larger cohort combining immunotherapy with conventional treatments. It builds on experimental treatment that prolonged the life of Professor Richard Scolyer, diagnosed with IDH wild-type GBM in 2023, giving hope for more effective therapies. Parallel efforts in Australia will soon recruit patients at the Brain Cancer Centre in Melbourne.
Dr. Khasraw is the principal investigator leading the GIANT trial. He is coordinating the multi-center study, framing the trial as “team science,” bringing together global clinicians and researchers to generate evidence that could transform GBM care.
Read the full article here.